AI assistant
DR REDDYS LABORATORIES LTD Earnings Release 2021
30528_rns_2021-07-07_866531da-d275-471d-b89b-437ac93e3ed6.pdf
Earnings Release
Open in viewerOpens in your device viewer
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India.
CIN: L85195TG1984PLC004507
Tel :+9140 4900 2900 Fax :+9140 4900 2999 Email :[email protected] www.drreddys.com
July 7, 2021
Corporate Relationship Department BSE Limited Dalal Street, Fort Mumbai - 400 001 Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039
National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 Fax Nos.: 022-26598120/ 26598237/ 26598238
Scrip Code: 500124
Scrip Code: DRREDDY-EQ
Dear Sir/ Madam,
Sub: Press Release
Please find enclosed a Press Release on "Dr. Reddy's to release Ql FY 22 results on July 27th, 2021 Earnings call slated for July 27th @ 5:30 PM 1ST / 8:00 AM EDT."
This is for your information.
With regards,
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd
DR. REDDY'$ LABORATORIES LTD.
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India. AMIT AGARWAL
| USHAIYER |
|---|
Dr. Reddy's to release Q1 FY 22 results on July 27th , 2021 Earnings call slated for July 27th @ 5:30 PM 1ST / 8:00 AM EDT
Hyderabad, India, July 7 th , 2021
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce • results for the quarter ended June 30th , 2021 on Tuesday, July 27th , 2021 after the Board Meeting.
Summary of Events
| Event | Date and TimeII | MediumII |
|---|---|---|
| Release of financial results | July 27th, after the Board Meeting | Stock Exchange, Media, Companywebsite, Business wire, Email |
| Press meet presentation | Will be available on the Company'swebsite | Company's websitewww.drreddY'.s.com |
| Earnings Call | July 27th, 5:30 PM 1ST / 8:00 AM EDT | Hosted by the Company(Details below) |
| Playback of Earnings Call | nd,After the earnings call till August 22021 | Details below |
| Transcript of the Earnings call | Will be available on the Company'swebsite | Company's websitewww.drreddY'.S,COm |
Earnings Call
Following the release, the management of the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given below)
Play Back
The play back will be available after the earnings call, till August 2 nd , 2021. For play back dial in phone No: +91 22 7194 5757 I +91 22 6663 5757, and Playback Code is 51225.
Conference Joining Information
Option 1: Express Join with Diamond Pass rM
Pre-register with the below link and join without waiting for the operator.
| Option 2: Join through below Dial•ln Numbers | |
|---|---|
| Universal Access Number: | +91 22 6280 1219+91 22 7115 8120 |
| International Toll Free Number: | USA: 1 866 746 2133UK: 0 808 101 1573Singapore: 800 101 2045Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may'', "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters. epidemics. pandemics or other widespread illness. including coronavirus (or COVID-19). and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "For-Nard-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any informaticn contained herei�
The company assurres no otligat1on to update any information contained herein